Clinical trials: Metformin, completed
Type 2 Diabetes, Obese Diabetics
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
This study explores the long-term effects of dapagliflozin and empagliflozin on CYP8B1 gene expression and a range of metabolic, oxidative, and inflammatory biomarkers in obese patients with Type 2 Diabetes Mellitus (T2DM).
- Conditions
- Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- CYP8B1-SGLT2-T (NCT07120828)
- Testing
- Empagliflozin (oral), Dapagliflozin (DAPA), Metfomin
- Where
- Iraq
- Volunteers
- 260 people
- Sponsor
- Erbil Polytechnic University
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Poor Glycemic Control
Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients
Most coronary artery bypass graft surgery (CABG) patients develop high blood sugar while they are in the hospital. No studies have shown what the best insulin regimen is for CABG patients with type 2 diabetes is after going home…
- Trial name
- CABG-D/C (NCT01792830)
- Testing
- Metformin, Glargine insulin, Glulisine
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT06161844
- Testing
- semaglutide injection (HD1916), Ozempic®
- Where
- China
- Volunteers
- 506 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Breast Cancer
Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients
The investigators hypothesize that adjuvant metformin use in breast cancer patients with overweight or pre-diabetes mellitus (DM) may improve their body condition including weight loss.
- Trial name
- NCT00909506
- Testing
- Metformin
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Seoul National University Hospital
Type2diabetes
Effects of Metformin Therapy on Pancreatic and Hepatic Fat Content in Patients of Type 2 Diabetes Mellitus
A sample size of 15 patients with T2DM visiting Fortis C DOC Hospital will be recruited with informed, written consent and will be requested to answer a validated questionnaire in a language known to them (English/Hindi).
- Trial name
- NCT05939921
- Testing
- Metformin
- Where
- India
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Type 2 Diabetes Mellitus
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
The objective of this study is to evaluate the efficacy on glycemic variability and safety of gemigliptin 50 mg orally administered once daily for 12 weeks compared with Dapagliflozin 10mg in patients with type 2 diabetes…
- Trial name
- NCT03202563
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg, Diet/exercise questionnaire
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- LG Chem
Type 2 Diabetes
Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D
Objectives: To quantify differences in control of glycemia (primary objective) and the secretion of endogenous incretin hormones (secondary objective) comparing sitagliptin or placebo added to pre-existing therapy with…
- Trial name
- NCT01937598
- Testing
- Mixed meal test, Liraglutide, Sitagliptin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Michael A. Nauck
NAFLD
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic disease ranging from fat accumulation in liver to fibrosis and cirrhosis. It affects 25% of the world population on average.
- Trial name
- NCT05521633
- Testing
- Metformin and Pioglitazone
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- King Edward Medical University
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes
The aim of the present study is to investigate the influence of several anti-diabetic regimens (metformin,glitazone,sulfonylurea,glinidine) and diet on metabolic parameters in patients with recently diagnosed type 2 diabetes.
- Trial name
- NCT00373178
- Testing
- rosiglitazone, metformin, Anti-diabetic medications
- Where
- 2 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Aristotle University Of Thessaloniki
Obesity
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
This is Open multicenter randomized Phase IV study to evaluate the efficacy and safety of the drug Reduxin® Forte, film-coated tablets, in comparison with the drug Reduxin®, capsules, in patients with alimentary obesity was…
- Trial name
- NCT05821543
- Testing
- metformin+sibutramine, sibutramine+ microcrystalline cellulose
- Where
- 8 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Promomed, LLC
Pre Diabetes
Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)
Patients with prediabetes can significantly reduce their risk of developing type 2 diabetes mellitus (T2DM) by participating in a Diabetes Prevention Program (DPP) or using metformin, but very few patients with prediabetes engage…
- Trial name
- BEST (NCT04902326)
- Testing
- Automated educational text messages, Autonomy-supportive automated educational text messages, Financial incentives
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- University of Michigan
Healthy
A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers
The purpose of the study is to investigate the potential interaction between multiple oral doses of canagliflozin and a single oral dose of metformin in healthy adult volunteers.
- Trial name
- NCT01273571
- Testing
- Canagliflozin/Metformin
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Extended phase 1 trial of combined metformin and erlotinib in advanced triple negative breast cancer patients. The goals of the study are to establish the maximum tolerated combined dosing of erlotinib and metformin as well as…
- Trial name
- NCT01650506
- Testing
- Metformin, Erlotinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Metformin Combined With Chemotherapy for Pancreatic Cancer
Pancreatic cancer patients have one of the worst prognoses among all cancer types with a 5 year survival rate of less than 5%. Despite significant changes during the last decade in our molecular knowledge on this disease, the…
- Trial name
- GEM (NCT01210911)
- Testing
- gemcitabine, erlotinib, metformin
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Type2 Diabetes
PilAm Go4Health Weight Loss Program to Prevent Heart Disease
This is a pilot randomized controlled trial intervention to improve lifestyle behaviors (physical activity and health diet) for Filipino Americans with type 2 diabetes on metformin.
- Trial name
- NCT02290184
- Testing
- PilAm Go4Health Weight-loss Program, Active Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Type 2 Diabetes
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.
Objective: To study Bioequivalence of Metformin Hydrochloride Extended Release 750 mg Tablets (Test formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference formulation, Bristol-Myers…
- Trial name
- NCT01089192
- Testing
- Metformin
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Type 2 Diabetes Mellitus
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus. In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and…
- Trial name
- NCT01677299
- Testing
- EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Elcelyx Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.